OMND — Optimind Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- CA$0.52m
- CA$0.53m
- CA$0.12m
- 17
- 28
- 22
- 10
Annual cashflow statement for Optimind Pharma, fiscal year end - February 28th, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2023 February 28th | 2024 February 29th | 2025 February 28th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | Final | Final | Final |
| Net Income/Starting Line | 0.131 | -0.172 | -3.08 | -1.4 | -0.216 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -0.207 | 0.094 | 2.13 | 0.811 | 0 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.022 | -0.003 | -0.128 | 0.105 | 0.001 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -0.098 | -0.081 | -1.04 | -0.47 | -0.215 |
| Other Investing Cash Flow Items | — | — | -0.221 | -0.023 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | — | -0.221 | -0.023 | 0 |
| Financing Cash Flow Items | -0.004 | 0 | 0.001 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.094 | 0.076 | -0.045 | -0.03 | 0.27 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.003 | -0.006 | -1.31 | -0.524 | 0.055 |